Evidence map›Paper›PMID 39131263›Full record

ArticleGastro hep advances2022

Fibrosis-3 Index: A New Score to Predict Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Without Age as a Factor.

Kazuya Kariyama, Miwa Kawanaka, Kazuhiro Nouso, Atsushi Hiraoka, Hidenori Toyoda, Toshifumi Tada, Toru Ishikawa, Akiko Wakuta, Nozomi Miyake, Shiho Murakami and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Gastro hep advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07791589 (Fibrosis Versus Metabolic Risk in MASLD), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07791589 completednot on this mapstarted 2026, after this paper: background citation

Fibrosis Versus Metabolic Risk in MASLD: Age-Adjusted Associations With PREVENT Cardiovascular Risk

TypeobservationalSponsorÖzgür BahadırRan2026 to 2026Enrolled271ConditionsMetabolic Dysfunction-Associated Steatotic Liver Disease
3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Usefulness of the Fibrosis-3 index in patients with hepatitis C.Annals of medicine and surgery (2012) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Identification of risk groups for advanced liver fibrosis in the general population using the Fibrosis-3 index.JGH open : an open access journal of gastroenterology and hepatology · 2024
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kazuya KariyamaDepartment of Gastroenterology and Liver Disease Center, Okayama City Hospital, Okayama City, Okayama, Japan.
Miwa KawanakaDepartment of General Internal Medicine 2, General Medical Center, Kawasaki Medical School, Okayma City, Okayama, Japan.
Kazuhiro NousoDepartment of Gastroenterology and Liver Disease Center, Okayama City Hospital, Okayama City, Okayama, Japan.
Atsushi HiraokaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama City, Ehime, Japan.
Hidenori ToyodaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki City, Gifu, Japan.
Toshifumi TadaDepartment of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Himeji City, Hyogo, Japan.
Toru IshikawaDepartment of gastroenterology, Saiseikai Niigata Hospital, Niigata City, Niigata, Japan.
Akiko WakutaDepartment of Gastroenterology and Liver Disease Center, Okayama City Hospital, Okayama City, Okayama, Japan.
Nozomi MiyakeDepartment of Gastroenterology and Liver Disease Center, Okayama City Hospital, Okayama City, Okayama, Japan.
Shiho MurakamiDepartment of Gastroenterology and Liver Disease Center, Okayama City Hospital, Okayama City, Okayama, Japan.
Shohei ShiotaDepartment of Gastroenterology and Liver Disease Center, Okayama City Hospital, Okayama City, Okayama, Japan.
Takashi KumadaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki City, Gifu, Japan.
Real-Life Practice Experts for HCC (RELPEC) Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The Fibrosis-4 (FIB-4) index has been used to predict liver fibrosis in various liver diseases, including nonalcoholic fatty liver disease (NAFLD). Because the FIB-4 formula uses age, different cutoff values may be required for different age groups, making the interpretation difficult. To avoid the influence of age, we attempted to create a new score, the Fibrosis-3 (FIB-3) index. Methods: The FIB-3 index was created using a training cohort of 735 NAFLD cases using aspartate aminotransferase, alanine amino transferase, and platelet for predicting fibrosis. The abilities of the FIB-3 and FIB-4 indices were compared among different age groups in the training cohort and validation cohort with 324 patients. The FIB-3 index was also compared with other liver fibrosis indices. Results: The area under the receiver operating characteristic curve (AUROC) values of the FIB-3 and FIB-4 indices for predicting F3-F4 fibrosis were 0.764 and 0.762, respectively, in the training cohort. No difference in the AUROC values was observed between the 2 indices in the validation cohort. The differences in the accuracies of FIB-3 between elderly and nonelderly patients were 0.140 and 0.178, respectively, in each cohort and were smaller than those of FIB-4 index (0.199 and 0.336, respectively). Analysis using a joined cohort revealed that the AUROC of FIB-3 for predicting F3-F4 fibrosis (0.774) was the highest among the 5 fibrosis scores examined and was comparable to that of FIB-4. Conclusion: The FIB-3 index is an improved version of the FIB-4 index and can effectively predict liver fibrosis in patients with NAFLD.

Indexed as

AgeFIB-3 IndexFIB-4 IndexLiver FibrosisNonalcoholic Fatty Liver Disease

Identifiers

PMID39131263
PMCPMC11308097

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.